Targeted gene therapies are highly effective at stopping cancers, but the very abundance of the treatments, plus cost and sluggish change, are hindering access.
Previous Story
OpenAI’s Greg Brockman Backs Out of Second $25 Million Donation to A.I. Super PAC
Next Story
Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually Stops Working
